The 5-HT1A agonism is a feature of multiple pharmacotherapies, including aripiprizole, vilazadone and buspirone for schizophrenia, depression and anxiety disorders, respectively, suggesting complex and diverse behavioral effects resulting from the activation of this receptor.19, 20, 48, 49. This evidence concerns the gene HTR1A and major depressive disorder.